Monika Joshi, MD, MRCP, of Penn State Cancer Institute, contextualizes the results of the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma. She also comments on the anticipated impact of novel FGFR inhibitors, such as LOXO-435 and TYRA-300, for advanced urothelial carcinoma, as well as other FGFR-targeted therapies under investigation in previously untreated advanced urothelial carcinoma and non-muscle invasive disease. ...
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Ferring Pharmaceuticals has expanded their Adstiladrin clinical trial program to include 3 new studies in NMIBC.
The FDA has accepted the Investigational New Drug Application for UGN-103 for low-grade intermediate-risk NMIBC.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Some patients who meet the FDA criteria for “BCG-unresponsive” bladder cancer may benefit from additional BCG therapy.
Dr. Ferguson highlights the latest TAR-210 and TAR-200 data in select patients with non-muscle invasive bladder cancer.
Patients with stage pT1 NMIBC who received transurethral resection of bladder tumor were included in the trial.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
Signatera quantifies cancer and the time of any recurrence events to assist in identifying treatment options.
Advertisement
Advertisement
Latest News
The ARON-1 study investigated the efficacy of 1L treatment with TKIs versus IO-based combinations in patients with pRCC.
Researchers performed a post hoc analysis on patient data from the randomized, phase 3 LATITUDE trial.
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
